Daratumumab with bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma when an autologous stem cell transplant is suitable [ID6249]

In development
Reference number: GID-TA11254
Expected publication date: 13 May 2026

Documents

Documents created during the development process.

Draft guidance

Draft guidance
Committee papers (PDF 8.89 MB)

Published:

14 January 2026
Equality impact assessment (downloadable version) (PDF 140 KB)

Published:

14 January 2026
Public committee slides (PDF 1.14 MB)

Published:

14 January 2026
Draft guidance (online commenting)
Draft guidance (downloadable version) (PDF 260 KB)

Published:

14 January 2026

Invitation to participate

NICE's response to comments on the draft scope and provisional stakeholder list (PDF 227 KB)

Published:

13 May 2025
Equality impact assessment (scoping) (PDF 103 KB)

Published:

13 May 2025
Final stakeholder list (PDF 135 KB)

Published:

13 May 2025
Final scope (PDF 126 KB)

Published:

13 May 2025

Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6249

Draft scope post referral (PDF 106 KB)

Published:

17 March 2025
Draft matrix post referral (PDF 98 KB)

Published:

17 March 2025